Pharmaceuticals News and Research

RSS

New position paper outlines national approach to antimicrobial stewardship

As the supply of life-saving antibiotics becomes increasingly threatened, infectious diseases experts urge healthcare systems and policymakers to step up efforts to protect patients by preserving the effectiveness of available antibiotics through antimicrobial stewardship initiatives.

15 Mar 2012

Teva commences commercial launch of Escitalopram Oxalate Tablets

Teva Pharmaceutical Industries Ltd. announced today that it has commenced commercial launch of Escitalopram Oxalate Tablets, the Company's generic version of Forest Laboratories' depression and generalized anxiety disorder treatment, Lexapro Tablets.

15 Mar 2012

Bayer HealthCare receives FDA approval for Natazia to treat HMB

Bayer HealthCare Pharmaceuticals Inc. today announced that the U.S. Food and Drug Administration (FDA) has approved a new indication for Natazia (estradiol valerate and estradiol valerate/dienogest) tablets for the treatment of heavy menstrual bleeding (HMB) that is not caused by any diagnosed conditions of the uterus (womb), in women who choose an oral contraceptive (OC) for contraception.

15 Mar 2012

EffRx receives FDA approval for BINOSTO to treat osteoporosis

EffRx Pharmaceuticals SA today announced that the U.S. Food and Drug Administration (FDA) has approved BINOSTO (alendronate sodium) Effervescent Tablets, previously known as EX101, for the treatment of osteoporosis in postmenopausal women, and as a treatment to increase bone mass in men with osteoporosis. EffRx anticipates that BINOSTO will be commercially available in the United States in the third quarter of 2012.

15 Mar 2012

Publicly available profile of effects of approved and investigational medicines

The National Institutes of Health and Eli Lilly and Company will generate a publicly available resource to profile the effects of thousands of approved and investigational medicines in a variety of sophisticated disease-relevant testing systems, NIH announced today.

14 Mar 2012

Microbubbles and focused ultrasound help drugs enter the brain

One of the trickiest parts of treating brain conditions is the blood brain barrier, a blockade of cells that prevent both harmful toxins and helpful pharmaceuticals from getting to the body's control center. But, a technique published in JoVE, uses an MRI machine to guide the use of microbubbles and focused ultrasound to help drugs enter the brain, which may open new treatment avenues for devastating conditions like Alzheimer's and brain cancers.

14 Mar 2012

FDA panel favors continued research on novel pain medicine

A panel of experts for the U.S. Food and Drugs Administration (FDA) this Monday recommended that the federal government should allow continued testing of an experimental class of pain drugs for arthritis, despite links to bone decay and joint failure.

13 Mar 2012

Insmed fourth quarter revenues increase to $1.4 million

Insmed Incorporated, a biopharmaceutical company, today reported results for the fourth quarter and fiscal year ended December 31, 2011.

13 Mar 2012

Bend Research announces licensing agreement with Affinium

Bend Research Inc., a leading independent drug-formulation development and manufacturing company, today announced a licensing agreement with Affinium Pharmaceuticals, Ltd.

13 Mar 2012

Inovio achieves strong T cell immune responses in PENNVAX-B Phase I HIV study

Inovio Pharmaceuticals, Inc. announced today that it has achieved strong T cell immune responses in a Phase I clinical study of PENNVAX-B, its product for the treatment of the HIV subtype prevalent in North America and Europe, in HIV-positive subjects.

13 Mar 2012

Thermo Fisher launches innovations that enable customers to improve lab productivity

Thermo Fisher Scientific Inc., the world leader in serving science, today introduced innovations that enable customers to improve laboratory productivity - by delivering results faster and with greater accuracy - while extending the boundaries of routine analysis. During Pittcon, being held from March 11-15, in Orlando, the company will showcase its scale and depth of capabilities across its three premier brands: Thermo Scientific, Fisher Scientific and Unity Lab Services.

From Thermo Fisher Scientific Inc. 13 Mar 2012

Agennix, DSM sign new contract to manufacture talactoferrin for NSCLC

DSM Pharmaceutical Products, the custom manufacturing business of Royal DSM N.V., and Agennix AG have signed a new contract under which DSM will continue to manufacture talactoferrin for Agennix at commercial levels.

13 Mar 2012

Positive results from Bausch + Lomb, NicOx BOL‑303259‑X phase 2b study on OAG

Bausch + Lomb, the global eye health company, and NicOx S.A. today announced positive top-line results from the phase 2b study conducted with BOL‑303259‑X, a novel nitric oxide-donating prostaglandin F2‑alpha analog, in patients with open-angle glaucoma or ocular hypertension.

13 Mar 2012

Einstein earns an 'A' for conflict-of-interest policies from AMSA

Albert Einstein College of Medicine of Yeshiva University has earned an "A," the top mark, for its conflict-of-interest policies from the American Medical Student Association (AMSA), the oldest and largest independent association of physicians-in-training in the United States.

13 Mar 2012

Medivir initiates two new HPC3001 and HPC3011 phase III trials in HCV

MedivirAB a research based specialty pharmaceutical company focused on infectious diseases announces that its oral, once daily investigational protease inhibitor TMC435, developed by Janssen Pharmaceuticals for the treatment of Hepatitis C virus (HCV), has commenced patient dosing and started screening in two new phase III clinical trials, HPC3001 and HPC3011, respectively.

13 Mar 2012

Thermo Fisher introduces Dionex ICS-5000 system

Thermo Fisher Scientific Inc., the world leader in serving science, today introduced the Thermo Scientific Dionex ICS-5000, a capillary high-pressure ion chromatography system that increases separation speeds and provides sharper peaks for high-efficiency ion chromatography.

From Thermo Fisher Scientific Inc. 13 Mar 2012

Trudeau Institute creates TICRO to expand the scope of biomedical research

The Trudeau Institute announced today that it has expanded the scope of its biomedical research by creating a contract research organization (CRO), the Trudeau Institute Contract Research Organization.

13 Mar 2012

Santorum's message: Romney would face trouble against Obama on health issues

GOP presidential hopeful Rick Santorum continues to attack rival Mitt Romney's Massachusetts' health reform record, arguing that it weakens his ability to run against President Barack Obama, and candidate Newt Gingrich also is not escaping the criticism.

13 Mar 2012

Reviva to initiate enrollment in RP503 phase 2 study for schizophrenia

Reviva Pharmaceuticals, Inc., a privately held drug discovery and development company, today announced enrollment of patients in its phase 2 clinical study of RP503 for schizophrenia and schizoaffective disorder.

13 Mar 2012

DNDi commences Oxaborole SCYX-7158 Phase I clinical trial for sleeping sickness

The Drugs for Neglected Diseases initiative (DNDi) has commenced a Phase I clinical trial in healthy adults in Paris, France, to determine the safety and tolerability of a promising oral drug candidate Oxaborole SCYX-7158, to treat human African trypanosomiasis (HAT, or sleeping sickness) for stage 1 and stage 2 of the disease.

12 Mar 2012